Sugi Predict

Sugi Predict / Compounds / SCHEMBL89062

SCHEMBL89062

SCHEMBL89062

CC(C)(C)OC(=O)N1C[C@H](C(=O)O)C[C@H](C(=O)O)C1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.54
▸ HPGD P15428 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.46
▸ MEN1 O00255 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ USP2 O75604 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ RECQL P46063 1/20 0.43
▸ EPHX1 P07099 1/20 0.43
▸ CHRM2 P08172 1/20 0.42
▸ CHRM1 P11229 1/20 0.42
▸ CHRM3 P20309 1/20 0.42
▸ BTK Q06187 1/20 0.41
▸ EPHX2 P34913 1/20 0.41
▸ RORC P51449 1/20 0.41
▸ GPR119 Q8TDV5 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20220628 1.00 NR1H2 (0.54) NR1H2HPGDHSD17B10MEN1ALDH1A1
SCHEMBL57263 1.00 NR1H2 (0.54) NR1H2HPGDHSD17B10MEN1ALDH1A1
SCHEMBL7866668 0.93 NR1H2 (0.49) NR1H2HPGDHSD17B10MEN1ALDH1A1
SCHEMBL18806921 0.93 NR1H2 (0.49) NR1H2HPGDHSD17B10MEN1ALDH1A1
SCHEMBL14478714 0.93 NR1H2 (0.49) NR1H2HPGDHSD17B10MEN1ALDH1A1
SCHEMBL43159 0.92 NR1H2 (0.53) NR1H2HPGDHSD17B10MEN1ALDH1A1
SCHEMBL31460173 0.92 NR1H2 (0.48) NR1H2HPGDHSD17B10MEN1ALDH1A1
SCHEMBL13461234 0.91 NR1H2 (0.47) NR1H2HPGDHSD17B10MEN1ALDH1A1
SCHEMBL8301548 0.91 NR1H2 (0.47) NR1H2HPGDHSD17B10MEN1ALDH1A1
SCHEMBL7953060 0.91 NR1H2 (0.47) NR1H2HPGDHSD17B10MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3660040-B1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2025-06-18 — — EP disclosed
EP-4551218-A2 POTENT AND SELECTIVE IRREVERSIBLE INHIBITORS OF IRAK1 Dana-Farber Cancer Institute, Inc. (US) 2025-05-14 — — EP disclosed
EP-3666792-B1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2024-12-18 — — EP disclosed
WO-2024011116-A2 POTENT AND SELECTIVE IRREVERSIBLE INHIBITORS OF IRAK1 DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-01-11 — — WO disclosed
WO-2024011116-A2 POTENT AND SELECTIVE IRREVERSIBLE INHIBITORS OF IRAK1 DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-01-11 — — WO disclosed
US-20230310551-A1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2023-10-05 — — US disclosed
EP-3922260-A2 INSULIN RECEPTOR PARTIAL AGONISTS AND GLP-1 ANALOGUES MERCK SHARP & DOHME CORP. (US) 2021-12-15 — — EP disclosed
US-10953076-B2 Insulin receptor partial agonists and GLP-1 analogues MERCK SHARP & DOHME CORP. (US) 2021-03-23 — — US disclosed
US-10800827-B2 Insulin receptor partial agonists MERCK SHARP & DOHME CORP. (US) 2020-10-13 — — US disclosed
EP-3221343-B1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME (US) 2020-09-16 — — EP disclosed
US-20100137587-A1 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED 2010-06-03 — — US disclosed
US-20100137587-A1 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED 2010-06-03 — — US disclosed
WO-2009154300-A2 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-23 — — WO disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 — — US disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 — — US disclosed
WO-2009000811-A1 N5-(2-ETHOXYETHYL)-N3-(2-PYRIDINYL)-3,5-PIPERIDINEDICARBOXAMIDE DERIVATIVES FOR USE AS RENIN INHIBITORS NOVARTIS AG (CH) 2008-12-31 — — WO disclosed
US-20080319018-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2008-12-25 — — US disclosed
US-20080194629-A1 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors BAESCHLIN DANIEL KASPAR 2008-08-14 — — US disclosed
US-20080194629-A1 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors BAESCHLIN DANIEL KASPAR 2008-08-14 — — US disclosed
WO-2007077005-A1 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS NOVARTIS AG (CH) 2007-07-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10800827-B2 Insulin receptor partial agonists INSR, GPR119, IRS1 NR1H2 231/4885HPGD 3295/4885HSD17B10 2172/4885
US-20090192148-A1 Organic Compounds REN, ACE, AGTR1 NR1H2 1327/4885HPGD 723/4885HSD17B10 2045/4885
US-20080319018-A1 ORGANIC COMPOUNDS REN, ACE, AGTR1 NR1H2 333/4885HPGD 599/4885HSD17B10 757/4885
US-10953076-B2 Insulin receptor partial agonists and GLP-1 analogues GLP1R, GIPR, IAPP NR1H2 410/4885HPGD 3263/4885HSD17B10 1928/4885
US-20080194629-A1 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors REN, ACE, AGTR1 NR1H2 3700/4885HPGD 435/4885HSD17B10 2865/4885
US-20100137587-A1 Heterocyclic compound and use thereof REN, AGT, ACE NR1H2 548/4885HPGD 25/4885HSD17B10 375/4885
US-20230310551-A1 INSULIN RECEPTOR PARTIAL AGONISTS INSR, GPR119, IRS1 NR1H2 231/4885HPGD 3295/4885HSD17B10 2172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.